News

The three parties will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Under the deal, each company will bring

Both the firms will jointly work on a worldwide basis with the aim of bringing an important investigational therapy to patients. Pfizer senior vice president and chief scientific

PXVX0200 uses the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol. The company plans to submit a Biologics

The trial is designed to evaluate the safety and efficacy of ADXS-PSA as a monotherapy and in combination with Merck’s Keytruda, the first anti-PD-1 (programmed death receptor-1) therapy

The trial is designed to evaluate the safety of talimogene laherparepvec in combination with Merck’s FDA approved, anti-PD-1 therapy Keytruda, as well as the efficacy of this combination

As part of the deal, Merck will pay about $102 per share in cash, which represents a 35% premium to Cubist’s average stock price for the most recent

VAX2012Q incorporates a bacterial flagellin protein designed to improve the adaptive immune response to the vaccine. The trial is designed to evaluate the vaccine’s safety and immunogenicity in

The sNDA for a monotherapy indication is based on data from two double-blind, historical-controlled, multicenter randomized, Phase III trials (093-046 and 093-045) with identical study designs. The trials

The company said that Vimizim was reviewed under the Orphan Drug program and it is the first treatment approved in Australia for Morquio A syndrome, an ultra-rare, severely